Dianon Pathology offers a comprehensive menu of assays and services to aid in the diagnosis, prognosis, and monitoring of dermatological conditions. In addition, Dianon’s advanced immunohistochemistry staining techniques allow for tissue conservation on small samples.

Scientific Expertise

Experienced specialty pathology staff

Dianon's dermatopathologists are subspecialty trained and further accomplished through extensive practical exposure. 

Daily intradepartmental review of melanomas and challenging cases

Daily review ensures accurate diagnoses. More than one dermatopathologist reviews melanomas and difficult cases, providing a built-in second opinion.

Expert consultants

Dianon maintains relationships with nationally recognized leaders in dermatopathology and utilizes these professionals to review challenging cases.

Technological enhancements

Dianon validates and applies the newest laboratory methods and technologies in the delivery of accurate and definitive diagnoses.

Advanced Assays for Melanoma

Melanoma FISH

Dianon offers a melanoma FISH panel that can help dermatopathologists diagnose ambiguous skin lesions. This FISH panel consists of RREB1 (6p25), MYB (6q23), 6 centromere, and CCND1 (11q13) and can be useful in differentiating melanomas from benign nevi. The test is available as a stand-alone or can be ordered as a reflex test for lesions deemed ambiguous or suspicious for melanoma by our dermatopathologists.

BRAF Gene Mutation Analysis

In patients with malignant melanoma, a mutation in the BRAF gene has been found to significantly improve response rates to therapy using vemurafenib (Zelboraf®*). Dianon offers a BRAF mutation test that is approved by the FDA as a companion diagnostic.

Dianon offers an extensive list of immunohistochemistry including:

  • Keratin markers for diagnosing carcinomas, including AE1/AE3, CK5/6, CK7, and CK20
  • Markers for diagnosing melanocytic lesions, including S-100 protein, Melan-A, HMB45, and MiTF
  • CD markers for diagnosing lymphoproliferative disorders, including CD3/20/30/4/5/7/8/10/43/45
  • Markers for diagnosing sarcomas including vimentin, desmin, and HHV-8

In situ hybridization and direct immunoflorescence

  • Human papillomavirus (HPV) testing by in situ hybridization (ISH) for low- and high-risk HPV subtyping
  • Direct immunofluorescence (DIF) test for immunobullous disorders and collagen vascular diseases


*Zelboraf is a registered trademark of Genentech, Inc.